Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD

Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD

Introduction: Patients with phospholipase A2 receptor (PLA2R)–associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membrano...

Full description

Bibliographic Details
Main Authors: Nicolas Hanset, Emmanuel Esteve, Emmanuelle Plaisier, Catherine Johanet, Pierre-Antoine Michel, Jean-Jacques Boffa, Patrick Fievet, Laurent Mesnard, Johann Morelle, Pierre Ronco, Karine Dahan
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024919315918

Internet

http://www.sciencedirect.com/science/article/pii/S2468024919315918

Similar Items